OBJECTIVE: To evaluate the efficacy and biological effects of the gemcitabine/tanespimycin combination in patients with advanced ovarian and peritoneal cancer. To assess the effect of tanespimycin on tumor cells, levels of the chaperone proteins HSP90 and HSP70 were examined in peripheral blood mononuclear cells (PBMC) and paired tumor biopsy lysates. METHODS: Two-cohort phase II clinical trial. Patients were grouped according to prior gemcitabine therapy. All participants received tanespimycin 154 mg/m(2) on days 1 and 9 of cycle 1 and days 2 and 9 of subsequent cycles. Patients also received gemcitabine 750 mg/m(2) on day 8 of the first treatment cycle and days 1 and 8 of subsequent cycles. RESULTS: The tanespimycin/gemcitabine combination induced a partial response in 1 gemcitabine naïve patient and no partial responses in gemcitabine resistant patients. Stable disease was seen in 6 patients (2 gemcitabine naïve and 4 gemcitabine resistant). The most common toxicities were hematologic (anemia and neutropenia) as well as nausea and vomiting. Immunoblotting demonstrated limited upregulation of HSP70 but little or no change in levels of most client proteins in PBMC and paired tumor samples. CONCLUSIONS: Although well tolerated, the tanespimycin/gemcitabine combination exhibited limited anticancer activity in patients with advanced epithelial ovarian and primary peritoneal carcinoma, perhaps because of failure to significantly downregulate the client proteins at clinically achievable exposures.
OBJECTIVE: To evaluate the efficacy and biological effects of the gemcitabine/tanespimycin combination in patients with advanced ovarian and peritoneal cancer. To assess the effect of tanespimycin on tumor cells, levels of the chaperone proteins HSP90 and HSP70 were examined in peripheral blood mononuclear cells (PBMC) and paired tumor biopsy lysates. METHODS: Two-cohort phase II clinical trial. Patients were grouped according to prior gemcitabine therapy. All participants received tanespimycin 154 mg/m(2) on days 1 and 9 of cycle 1 and days 2 and 9 of subsequent cycles. Patients also received gemcitabine 750 mg/m(2) on day 8 of the first treatment cycle and days 1 and 8 of subsequent cycles. RESULTS: The tanespimycin/gemcitabine combination induced a partial response in 1 gemcitabine naïve patient and no partial responses in gemcitabine resistant patients. Stable disease was seen in 6 patients (2 gemcitabine naïve and 4 gemcitabine resistant). The most common toxicities were hematologic (anemia and neutropenia) as well as nausea and vomiting. Immunoblotting demonstrated limited upregulation of HSP70 but little or no change in levels of most client proteins in PBMC and paired tumor samples. CONCLUSIONS: Although well tolerated, the tanespimycin/gemcitabine combination exhibited limited anticancer activity in patients with advanced epithelial ovarian and primary peritoneal carcinoma, perhaps because of failure to significantly downregulate the client proteins at clinically achievable exposures.
Authors: Z Q Yuan; M Sun; R I Feldman; G Wang; X Ma; C Jiang; D Coppola; S V Nicosia; J Q Cheng Journal: Oncogene Date: 2000-05-04 Impact factor: 9.867
Authors: Paul G Richardson; Ashraf Z Badros; Sundar Jagannath; Stefano Tarantolo; Jeffrey L Wolf; Maher Albitar; David Berman; Marianne Messina; Kenneth C Anderson Journal: Br J Haematol Date: 2010-07-07 Impact factor: 6.998
Authors: Joleen Hubbard; Charles Erlichman; David O Toft; Rui Qin; Bridget A Stensgard; Sara Felten; Cynthia Ten Eyck; Gretchen Batzel; S Percy Ivy; Paul Haluska Journal: Invest New Drugs Date: 2010-01-15 Impact factor: 3.850
Authors: Adeela Kamal; Lia Thao; John Sensintaffar; Lin Zhang; Marcus F Boehm; Lawrence C Fritz; Francis J Burrows Journal: Nature Date: 2003-09-25 Impact factor: 49.962
Authors: Sonnet J H Arlander; Alex K Eapen; Benjamin T Vroman; Robert J McDonald; David O Toft; Larry M Karnitz Journal: J Biol Chem Date: 2003-10-21 Impact factor: 5.157
Authors: Hanqing Liu; Fang Xiao; Ilya G Serebriiskii; Shane W O'Brien; Marisa A Maglaty; Igor Astsaturov; Samuel Litwin; Lainie P Martin; David A Proia; Erica A Golemis; Denise C Connolly Journal: Clin Cancer Res Date: 2013-07-30 Impact factor: 12.531
Authors: Katrina S Pedersen; George P Kim; Nathan R Foster; Andrea Wang-Gillam; Charles Erlichman; Robert R McWilliams Journal: Invest New Drugs Date: 2015-05-08 Impact factor: 3.850
Authors: Andrew Lilja; Clare E Weeden; Kate McArthur; Thao Nguyen; Alastair Donald; Zi Xin Wong; Lovisa Dousha; Steve Bozinovski; Ross Vlahos; Christopher J Burns; Marie-Liesse Asselin-Labat; Gary P Anderson Journal: PLoS One Date: 2015-01-23 Impact factor: 3.240